This article is more than 5 years old. Information may no longer be current.

Heparosan drug delivery system to expand to insulin

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Caisson Biotech, LLC has partnered with Novo Nordisk to develop a herparosan-based drug delivery system for insulin.

“Novo Nordisk has completed feasibility studies that pre-clinically validate Caisson’s heparosan-based drug delivery technology for product pharmacokinetics and enhanced half-life,” Paul DeAngelis, PhD, chief scientist at Caisson, said in a press release. “The HEPtune technology uses heparosan, a naturally occurring sugar polymer produced by the body that is stable and inert in the bloodstream while being biodegradable.”

The license agreement gives Novo Nordisk exclusive rights to commercialize insulin conjugated to HEPtune and nonexclusive rights to use the delivery system for other therapeutic areas, according to the press release. Caisson announced they will be eligible to receive up to $167 million in milestones payments, plus royalties as products are sold, as a result of the partnership.